insight
🩹 성형 🏥 중증 🌐 전체
← 뒤로

Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma.

Med (New York, N.Y.) 2026 Vol.7(4) p. 101066

Kanemura H, Hayashi H

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

MRG003, a novel EGFR-targeted antibody-drug conjugate (ADC), demonstrates significant efficacy in heavily pretreated patients with recurrent or metastatic nasopharyngeal carcinoma.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Kanemura H, Hayashi H (2026). Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma.. Med (New York, N.Y.), 7(4), 101066. https://doi.org/10.1016/j.medj.2026.101066
MLA Kanemura H, et al.. "Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma.." Med (New York, N.Y.), vol. 7, no. 4, 2026, pp. 101066.
PMID 41966716
DOI 10.1016/j.medj.2026.101066

Abstract

MRG003, a novel EGFR-targeted antibody-drug conjugate (ADC), demonstrates significant efficacy in heavily pretreated patients with recurrent or metastatic nasopharyngeal carcinoma. With an objective response rate of 42% and encouraging overall survival, MRG003 appears to overcome previous limitations of EGFR therapies. Its manageable safety profile and bystander-killing effect highlight the potential of ADCs to revolutionize treatment paradigms in this population.

MeSH Terms

Humans; Nasopharyngeal Carcinoma; ErbB Receptors; Nasopharyngeal Neoplasms; Immunoconjugates; Molecular Targeted Therapy; Antineoplastic Agents

같은 제1저자의 인용 많은 논문 (1)